Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01650870 · ClinicalTrials.gov registry record · Phase 2

Safety, Efficacy, and Patient Preference of Split-Dose Crystalline Lactulose as a Preparation for Colonoscopy in Adults

A Phase 2 study of Colonoscopy, sponsored by Benaroya Research Institute.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT01650870 is a Phase 2 study of Colonoscopy that has completed, run by Benaroya Research Institute. The registered enrollment target is 40 participants, below the 500-participant average among 20 other Colonoscopy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01650870, a Phase 2 study of Colonoscopy, has completed, sponsored by Benaroya Research Institute.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the efficacy of a split-dose regimen of crystalline lactulose for cleansing of the colon as a preparation for colonoscopy, as assessed by the physician's determination of the cleanliness of the colon using the Boston Bowel Prep Scale (BBPS).

Conditions Studied

Interventions

  • DRUG Crystalline Lactulose

Study Locations (1)

Washington

  • Virginia Mason Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2012-07
Est. Completion 2012-09
Phase Phase 2

Sponsor

Benaroya Research Institute

28 total trials

What the Registry Record Tells You About NCT01650870

The ClinicalTrials.gov registry entry for NCT01650870 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 500-participant average among 20 other Colonoscopy trials with a reported enrollment target (92% lower). The listed sponsor is Benaroya Research Institute, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Colonoscopy appearing as the primary indexed condition, and to 1 intervention - of which Crystalline Lactulose is the first listed.

NCT01650870 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT01650870 about?

NCT01650870 is a clinical study titled "Safety, Efficacy, and Patient Preference of Split-Dose Crystalline Lactulose as a Preparation for Colonoscopy in Adults". The purpose of this study is to determine the efficacy of a split-dose regimen of crystalline lactulose for cleansing of the colon as a preparation for colonoscopy, as assessed by the physician's determination of the cleanliness of the colon using the Boston Bowel Prep Scale (BBPS).

What is the current status of trial NCT01650870?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2012-07. Estimated completion is 2012-09.

What conditions does trial NCT01650870 study?

This clinical trial studies the following conditions: Colonoscopy.

What interventions are being tested in trial NCT01650870?

The interventions under investigation include: Crystalline Lactulose (DRUG).

Who is sponsoring clinical trial NCT01650870?

This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01650870 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colonoscopy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.